LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer

Inclusion Criteria: * DCIS (whether or not undergoing planned SLNB) or patients with Stage I-II, primary invasive carcinoma of the breast undergoing SLNB for which the patient's primary surgical treatment is single breast partial mastectomy. * ECOG performance status of 0 to 2 Exclusion Criteria: * Contraindications for surgery. * Simultaneous bilateral lumpectomies and bilateral partial mastectomies. * History of drug-related anaphylactic reactions, including those attributed to indocyanine green (ICG) or other agents used in the study * Prior chemotherapy, endocrine therapy, or biologic therapy for current clinically or biopsy proven breast cancer for Period 1. * Open surgery in the ipsilateral breast within a period of 1 year before administration of LS301-IT. * History of radiation therapy to the chest. * The lymphatic imaging agent ICG cannot be used prior to the partial mastectomy and SLNB procedures on the day of surgery.